A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major

Vaccine

Volumn 22, Issue 13-14, 2004, Pages 1631-1639

  Ahmed, Sami Ben Hadj ^a   Bahloul, Chokri ^a   Robbana, Cyrine ^a   Askri, Souhir ^a   Dellagi, Koussay ^a  

^a PASTEUR INSTITUTE OF TUNIS   (Tunisia)

Author keywords

DNA; L. major; Murine leishmaniasis

Indexed keywords

ADJUVANT; ANTIGEN; ANTIGEN P20; ANTIGEN P24; DNA VACCINE; GP63 ANTIGEN; LACK ANTIGEN; LEIF ANTIGEN; PSA2 ANTIGEN; RIBOSOMAL LIKE PROTEIN ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; EVALUATION; EXPERIMENT; GENETIC CODE; IMMUNOSTIMULATION; LEISHMANIA MAJOR; LEISHMANIASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROTECTION; PROVOCATION TEST; TANDEM REPEAT; VIRULENCE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, BACTERIAL; KINETICS; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; PLASMIDS; PROTOZOAN VACCINES; VACCINES, DNA;

EID: 1842584437     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.10.046     Document Type: Article

References (34)

1. Pearson R.D., Sousa A. Clinical spectrum of leishmaniasis. Clin. Infect. Dis. 22(1):1996;1-13.
2. Sacks D., Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2(11):2002;845-858.
3. Greenblatt C.L. The present and the future of vaccination for cutaneous leishmaniasis. Prog. Clin. Biol. Res. 47:1980;259-285.
4. Scott P.E., Pearce E., Natovitz P., Sher A. Vaccination against leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes. J. Immunol. 139(1):1987;221-227.
5. Mayrink W.P., Williams P., Da Costa C.A., Magalhaes P.A., Melo M.N., Dias M.et al. An experimental vaccine against American dermal leishmaniasis: experience in the State of Espirito Santo, Brazil. Ann. Trop. Med. Parasitol. 79(3):1985;259-269.
6. Tang D.C., DeVit M., Johnston S.A. Genetic immunization is a simple method for eliciting an immune response. Nature. 356(6365):1992;152-154.
7. Taubes G. Salvation in a snippet of DNA? Science. 278(5344):1997;1711- 1714.
8. Xu D., Liew F. Genetic vaccination against leishmaniasis. Vaccine. 12(16):1994;1534-1536.
9. Gurunathan S., Sacks D.L., Brown D.R., Reiner S.L., Charest H., Glaichenhaus N.et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186(7):1997;1137-1147.
10. Stobie L., Gurunathan S., Prussin C., Sacks D.L., Glaichenhaus N., Wu C.Y.et al. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge. Proc. Natl. Acad. Sci. USA. 97(15):2000;8427-8432.
11. Mendez S., Gurunathan S., Kamhawi S., Belkaid Y., Moga M.A., Skeiky Y.A.et al. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J. Immunol. 166(8):2001;5122-5128.
12. Rafati S., Salmanian A.H., Taheri T., Vafa M., Fasel N. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine. 19(25-26):2001;3369-3375.
13. Handman E., Noormohammadi A.H., Curtis J.M., Baldwin T., Sjolander A. Therapy of murine cutaneous leishmaniasis by DNA vaccination. Vaccine. 18(26):2000;3011-3017.
14. Kebaier C., Louzir H., Chenik M., Ben Salah A., Dellagi K. Heterogeneity of wild Leishmania major isolates in experimental murine pathogenicity and specific immune response. Infect. Immunol. 69(8):2001;4906-4915.
15. Sjolander A., Baldwin T.M., Curtis J.M., Handman E. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis. J. Immunol. 160(8):1998;3949-3957.
16. Walker P., Scharton-Kersten T., Rowton E.D., Hengge U., Bouloc A., Udey M.C.et al. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of Leishmaniasis. Hum. Gene Ther. 9(13):1998;1899-1907.
17. Gurunathan S., Prussin C., Sacks D.L., Seder R.A. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat. Med. 4(12):1998;1409-1415.
18. Gurunathan S., Stobie L., Prussin C., Sacks D.L., Glaichenhaus N., Iwasaki A.et al. Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells. J. Immunol. 165(2):2000;915-924. (Erratum in: J Immunol 2000; 165(6):following 3526).
19. Soussi N., Milon G., Colle G.H., Mougeau E., Glaichenhaus N., Goossens P.L. Listeria monocytogenes as a short-lived delivery system for the induction of type 1 Cell-mediated immunity against the p36/LACK antigen of Leishmania major. Infect. Immunol. 68(3):2000;1498-1506.
20. Melby P.C., Yang J., Zhao W., Perez L.E., Cheng J. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immunol. 69(8):2001;4719-4725.
21. Gonzalo R.M., del Real G., Rodriguez J.R., Rodriguez D., Heljasvaara R., Lucas P.et al. A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. Vaccine. 20(7-8):2002;1226-1231.
22. Mougneau E., Altare F., Wakil A.E., Zheng S., Coppola T., Wang Z.E.et al. Expression cloning of a protective Leishmania antigen. Science. 268(5210):1995;563-566.
23. Julia V., Rassoulzadegan M., Glaichenhaus N. Resistance to Leishmania major induced by tolerance to a single antigen. Science. 274(5286):1996;421-423.
24. Launois P., Maillard I., Pingel S., Swihart K.G., Xenarios I., Acha-Orbea H.et al. IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity. 6(5):1997;541-549.
25. Pingel S., Launois P., Fowell D.J., Turck C.W., Southwood S., Sette A.et al. Altered ligands reveal limited plasticity in the T cell response to a pathogenic epitope. J. Exp. Med. 189(7):1999;1111-1120.
26. Locksley R.M., Pingel S., Lacy D., Wakil A., Bix M., Fowell D.J. Susceptibility to infectious diseases: Leishmania as a paradigm. J. Infect. Dis. 179(Suppl 2):1999;S305-S308.
27. Skeiky Y.A., Guderian J.A., Benson D.R., Bacelar O., Carvalho E.M., Kubin M.et al. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J. Exp. Med. 181(4):1995;1527-1537.
28. Probst P., Skeiky Y.A., Steeves M., Gervassi A., Grabstein K.H., Reed S.G. A Leishmania protein that modulates interleukin (IL)-12, IL-10 and tumor necrosis factor-alpha production and expression of B7-1 in human monocyte-derived antigen-presenting cells. Eur. J. Immunol. 27(10):1997;2634- 2642.
29. Skeiky Y.A., Kennedy M., Kaufman D., Borges M.M., Guderian J.A., Scholler J.K.et al. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J. Immunol. 161(11):1998;6171-6179.
30. Shimada S., Yano O., Tokunaga T. In vivo augmentation of natural killer cell activity with a deoxyribonucleic acid fraction of BCG. Jpn. J. Cancer Res. 77(8):1986;808-816.
31. Yamamoto S., Kuramoto E., Shimada S., Tokunaga T. In vitro augmentation of natural killer cell activity and production of interferon-alfa/beta and -gamma with deoxyribonucleic acid fraction from Mycobacterium bovis BCG. Jpn. J. Cancer Res. 79(7):1988;866-873.
32. Klinman D., Yi A.-E., Beaucage S., Conover J., Krieg A. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl. Acad. Sci. USA. 93(7):1996;2879-2883.
33. Halpern M., Kurlander R., Pisetsky D. Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alfa. Cell Immunol. 167(1):1996;72-78.
34. Sato Y., Roman M., Tighe H., Lee D., Corr M., Nguyen M.D.et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science. 273(5273):1996;352-354.